Ashland Launches permexa Sodium Caprate To Advance Oral Delivery Of Peptides, Biologics, And GLP‑1 Therapies
Ashland Inc. (NYSE:ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide,
Ashland made a new ingredient that helps medicines go through your stomach better so they work when you swallow them instead of needing shots. This is exciting because lots of companies want this technology, but we'll have to see if doctors and patients actually use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.